Open Access

Phospholipase A2inhibitors protect against prion and Aβ mediated synapse degeneration

Molecular Neurodegeneration20105:13

DOI: 10.1186/1750-1326-5-13

Received: 27 January 2010

Accepted: 8 April 2010

Published: 8 April 2010

Abstract

Background

An early event in the neuropathology of prion and Alzheimer's diseases is the loss of synapses and a corresponding reduction in the level of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission. The molecular mechanisms involved in synapse degeneration in these diseases are poorly understood. In this study the process of synapse degeneration was investigated by measuring the synaptophysin content of cultured neurones incubated with the prion derived peptide (PrP82-146) or with Aβ1-42, a peptide thought to trigger pathogenesis in Alzheimer's disease. A pharmacological approach was used to screen cell signalling pathways involved in synapse degeneration.

Results

Pre-treatment with phospholipase A2 inhibitors (AACOCF3, MAFP and aristolochic acids) protected against synapse degeneration in cultured cortical and hippocampal neurones incubated with PrP82-146 or Aβ1-42. Synapse degeneration was also observed following the addition of a specific phospholipase A2 activating peptide (PLAP) and the addition of PrP82-146 or Aβ1-42 activated cytoplasmic phospholipase A2 within synapses. Activation of phospholipase A2 is the first step in the generation of platelet-activating factor (PAF) and PAF receptor antagonists (ginkgolide B, Hexa-PAF and CV6029) protected against synapse degeneration induced by PrP82-146, Aβ1-42 and PLAP. PAF facilitated the production of prostaglandin E2, which also caused synapse degeneration and pre-treatment with the prostanoid E receptor antagonist AH13205 protected against PrP82-146, Aβ1-42 and PAF induced synapse degeneration.

Conclusions

Our results are consistent with the hypothesis that PrP82-146 and Aβ1-42trigger abnormal activation of cytoplasmic phospholipase A2 resident within synapses, resulting in elevated levels of PAF and prostaglandin E2that cause synapse degeneration. Inhibitors of this pathway that can cross the blood brain barrier may protect against the synapse degeneration seen during Alzheimer's or prion diseases.

Background

In the transmissible spongiform encephalopathies, otherwise known as the prion diseases, changes in synaptic function and a reduction in synaptophysin levels within the brain occur at a time before any gross neuronal loss is observed [13]. These synaptic alterations are associated with the accumulation of a differentially folded, and protease-resistant isoform (PrPSc), of the host encoded cellular prion protein (PrPC) [4]. The formation of PrPSc is accompanied by a decreased expression of proteins involved in exocytosis and neurotransmission, such as synaptophysin, SNAP-25 and synapsins in the brains of scrapie-infected mice [2, 5] and in humans affected with Creutzfeldt-Jakob disease (CJD) [6].

The molecular mechanisms that underlie synapse degeneration in prion diseases are not understood. Such processes have been examined by incubating cultured neurones with PrPSc or specific prion-derived peptides. A major PrP fragment spanning amino acid residues 81-82 to 144-153 was isolated from the brains of patients with the hereditary prion disease Gerstmann-Sträussler-Scheinker disease [7]. Synthetic peptides containing amino acid residues 82 to 146 (PrP82-146) had similar structural and biochemical properties to PrPSc suggesting that this fragment was the neurotoxic species generated in prion diseases. This hypothesis was strengthened by observations that both partially purified PrPSc preparations and PrP82-146 caused synapse degeneration in cortical and hippocampal neurones [8]. The effect of PrP82-146 on synapses in neuronal cultures was measured using an enzyme linked immunoassay (ELISA) to quantify the amount of synaptophysin [9]. Synaptophysin is a pre-synaptic membrane protein essential for neurotransmitter release and the recycling of synaptic vesicles and hence neurotransmission [1013]. The amount of synaptophysin has been used to access synaptic density in the brain [14, 15] and in cultured neurones [8]. Although immunocytochemistry is commonly used to examine synapse density this method is susceptible to errors in counting and field selection. The use of an ELISA overcame such problems by measuring synaptic density throughout neuronal cultures.

Synaptic failure is also thought to contribute to the neuropathogenesis of Alzheimer's disease (AD) [16] and the loss of synaptic proteins is the best correlate of dementia in AD [14, 1720]. The amyloid hypothesis of AD pathogenesis maintains that the primary event is the production of neurotoxic amyloid-β (Aβ) peptides following the proetolytic cleavage of the amyloid precursor protein into different fragments [21, 22]. These fragments include Aβ1-42 which is widely regarded as the main pathogenic species in AD. Recent studies showed the importance of small soluble oligomers of Aβ or Aβ derived diffusible ligands in neurotoxicity [23, 24]. In this study we sought to determine whether PrP82-146 and Aβ induced synapse degeneration was mediated through specific cell signalling pathways. We report that PrP82-146 and Aβ1-42 induced synapse degeneration was prevented by pharmacological inhibition of PLA2 and that both PrP82-146 and Aβ1-42 peptides increased activation of cytoplasmic phospholipase A2 (cPLA2) within synapses suggesting that activation of this enzyme triggers synapse degeneration. This hypothesis was supported by the observation that the synapse degeneration was also observed following the addition of a specific PLA2 activating peptide (PLAP). Activation of PLA2 is the first step in the production of bioactive prostaglandins and platelet-activating factor (PAF), specific antagonists of which also reduced PrP82-146 and Aβ1-42 induced synapse degeneration.

Results

PLA2inhibitors protected against PrP82-146 induced synapse degeneration

The addition of the prion derived peptide PrP82-146 reduced the synaptophysin content of cortical neurones indicative of a loss of synapses. This effect was a consequence of the specific amino acid sequence of PrP82-146 as a control peptide (PrP82-146scram) did not affect synapses [8]. The synaptophysin content was reduced by greater than 80% by 1 μM PrP82-146 (Figure 1A) which did not affect neuronal survival as measured by thiazyl blue tetrazolium (98% neuronal survival ± 6 compared with 100% ± 6, n = 9, P = 0.53). Immunoblot analysis showed that PrP82-146 caused a dose-related reduction in the amounts of synaptophysin in cell extracts without affecting the amounts of β-actin (Figure 1B).
Figure 1

PLA 2 inhibitors protected cortical neurones against PrP82-146 induced synapse degeneration. (A) The synaptophysin content of cortical neurones pre-treated for with a vehicle control (■), 1 μM AACOCF3 (), 1 μM MAFP (), 5 μg/ml aristolochic acid (□), 10 μM U73122 (▲) or 10 μM ethyl-18-OCH3 () and subsequently incubated with varying concentrations of PrP82-146 for 24 hours. Values shown are the mean average amount of synaptophysin ± standard deviation (SD), n = 15. (B) Immunoblots showing the amount of synaptophysin and β-actin in cell extracts from neurones incubated with PrP82-146 (1.25 - 0.05 μM).

To determine if the degeneration of synapses resulted from activation of specific cell signalling pathways cortical neurones were pre-treated with inhibitors of some common cell signalling pathways and incubated with PrP82-146. Pre-treatment with the PLA2 inhibitors (1 μM AACOCF3, 1 μM MAFP or 5 μg/ml aristolochic acids) protected against the PrP82-146 mediated decrease in synaptophysin (Figure 1A). The concentration of PrP82-146 required to reduce the synaptophysin content of vehicle treated cortical neurones by 50% (EC50) was approximately 60 nM. By comparison, the EC50 of PrP82-146 for cortical neurones treated with 1 μM AACOCF3 or 1 μM MAFP was greater than 10 μM, and in neurones pre-treated with 5 μg/ml aristolochic acids the EC50 was 5 μM. In contrast, pre-treatment with phospholipase C inhibitors (10 μM U73122 or ethyl-18-OCH3) did not affect the PrP82-146 induced loss of synaptophysin from cortical neurones. The synaptophysin content of neurones was not significantly affected by treatment with 5 μM AACOCF3 (100 units synaptophysin ± 4 compared to 101 ± 4, n = 12, P = 0.5), 5 μM MAFP (100 ± 4 v 102 ± 6, n = 12, P = 0.4) or 5 μg/ml aristolochic acids (100 ± 4 compared to 98 ± 4, n = 12, P = 0.2) alone showing that these drugs did not stimulate synaptogenesis, nor did they damage synapses.

PLA2inhibitors protected hippocampal neurones against PrP82-146 induced synapse degeneration

To determine if the effect of PLA2 inhibitors was selective for cortical neurones, their effect on hippocampal neurones was also examined. PrP82-146 reduced the amount of synaptophysin in hippocampal neurones; the EC50 of PrP82-146 in hippocampal neurones was 10 nM and while the addition of 200 nM PrP82-146 reduced the synaptophysin content to 20% of control cultures, it did not alter cell survival as measured by thiazyl blue tetrazolium (97% cell survival ± 7 compared with 100% ± 9, n = 9, P = 0.7). Pre-treatment with 1 μM AACOCF3 or 1 μM MAFP prevented the PrP82-146 mediated decrease in the synaptophysin content of hippocampal neurones and in treated neurones the EC50 was increased to greater than 1 μM (Figure 2).
Figure 2

PLA 2 inhibitors protected hippocampal neurones against PrP82-146 induced synapse degeneration. The synaptophysin content of cultured hippocampal neurones pre-treated with a vehicle control (■), 1 μM AACOCF3 () or 1 μM MAFP () and incubated with varying concentrations of PrP82-146 for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 9.

PLA2 inhibitors protected against synapse degeneration induced by Aβ1-42

The synapse degeneration that occurs in AD is thought to be caused by Aβ1-42 [25, 26]. This process can be modelled in vitro and the addition of Aβ1-42, but not Aβ42-1, reduced the synaptophysin content of cultured cortical and hippocampal neurones [27]. Here we report that pre-treatment with 1 μM AACOCF3 or 1 μM MAFP protected cortical neurones against the Aβ1-42 induced reduction in synaptophysin content (Figure 3A). While the EC50 of Aβ1-42 in vehicle treated cortical neurones was 50 nM, the EC50 of Aβ1-42 for cortical neurones treated with 1 μM AACOCF3 was greater than 10 μM. PLA2 inhibitors also protected hippocampal neurones against Aβ1-42 induced synapse degeneration. Thus, the EC50 of Aβ1-42 for vehicle treated hippocampal neurones was 10 nM, while in hippocampal neurones pre-treated with 1 μM AACOCF3 the EC50 of Aβ1-42 was increased to greater than 1 μM (Figure 3B).
Figure 3

PLA 2 inhibitors protected against Aβ 1-42 induced synapse degeneration. (A) The synaptophysin content of cortical neurones pre-treated with a vehicle control (■), 1 μM AACOCF3 () or 1 μM MAFP () and incubated with varying concentrations of Aβ1-42 for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12. (B) The synaptophysin content of hippocampal neurones pre-treated with a vehicle control (■) or 1 μM AACOCF3 () and incubated with varying concentrations of Aβ1-42 for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 6.

Conditioned medium from 7PA2 cells (7PA2-CM), which contains naturally secreted Aβ oligomers [28], also reduced the synaptophysin content of cortical neurones, whereas conditioned medium from non-transfected Chinese hamster ovary cells (CHO-CM), which did not contain Aβ oligomers, had no affect (Figure 4A). Pre-treatment of cortical neurones with either 1 μM AACOCF3 or 1 μM MAFP prevented the 7PA2-CM mediated decrease in synaptophysin (Figure 4B).
Figure 4

PLA 2 inhibitors protected against 7PA2-CM induced synapse degeneration. (A) The synaptophysin content of cortical neurones incubated for 24 hours with 7PA2-CM (□) or CHO-CM (■). Values shown are the mean average amount of synaptophysin ± SD, n = 12. (B) The synaptophysin content of cortical neurones incubated for pre-treated with a vehicle control (□), 1 μM AACOCF3 (■) or 1 μM MAFP (striped bars) and incubated with doubling dilutions of 7PA2-CM for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12.

PLA2inhibitors did not affect the accumulation of PrP82-146 in synapses

Prior studies showed that PrP82-146 accumulated within synaptosomes isolated from cortical neurones prior to synaptic degeneration [8]. That observation raised the possibility that the protective effect of PLA2 inhibitors might be because they reduced the binding/accumulation of PrP82-146 within synapses. Firstly, we showed that the amount of synaptophysin was not significantly different between synaptosomes isolated from cortical neurones and neurones treated 1 μM AACOCF3 or 1 μM MAFP; indicating that these drugs did not affect synapse formation. Next cortical neurones were pre-treated with 1 μM AACOCF3 before the addition of 100 nM PrP82-146. The amount of PrP82-146 found within synaptosomes isolated from vehicle and AACOCF3 treated neurones were not significantly different (Figure 5). Similar results were obtained with synaptosomes from cortical neurones pre-treated with 1 μM MAFP indicating that the PLA2 inhibitors did not prevent the binding or transport of PrP82-146 to synapses.
Figure 5

PLA 2 inhibitors did not affect the accumulation of PrP82-146 in synapses. The amount of PrP82-146 detected in synaptosomes isolated from cortical neurones incubated with a vehicle control (■), 1 μM AACOCF3 (□) or 1 μM MAFP (striped bars). Treated cortical neurones were incubated with 100 nM PrP82-146 for the time periods shown. Synaptosomes were isolated from neuronal cultures and the amount of PrP82-146 was measured by ELISA. Values shown are the mean average amount of PrP82-146 (nM) ± SD, n = 9.

PLA2inhibitors protected against synapse degeneration induced by PLAP

Next we sought to determine whether synapse degeneration resulted from activation of an endogenous PLA2. The addition of PLAP, a peptide that activated endogenous cPLA2 [29, 30], had similar effects as PrP82-146 and Aβ1-42 on synapses; it reduced the synaptophysin content of cortical neurones in a dose dependent manner. The addition of 1 μM PLAP reduced the synaptophysin content of cultured neurones by approximately 80% without affecting the survival of neurones as measured by thiazyl blue tetrazolium (96% neuronal survival ± 5 compared with 100% ± 8, n = 9, P = 0.7). Pre-treatment with 1 μM AACOCF3 or 1 μM MAFP protected cortical neurones against PLAP induced synapse degeneration; in vehicle treated neurones the EC50 of PLAP was 100 nM, while in neurones pre-treated with 1 μM AACOCF3 or 1 μM MAFP the addition of 1 μM PLAP did not reduce the synaptophysin content by more than 20% (Figure 6).
Figure 6

PLA 2 inhibitors protected against PLAP induced synapse degeneration. The synaptophysin content of cortical neurones pre-treated with a vehicle control (■), 1 μM AACOCF3 () or 1 μM MAFP () and incubated with varying concentrations of PLAP for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12.

cPLA2is enriched in synaptosomes

To investigate the hypothesis that synapse degeneration resulted from activation of an endogenous cPLA2, the amount of cPLA2 protein in synaptosomes was measured. The cPLA2 protein was enriched in synaptosomes isolated from cortical neurones compared to whole cell membrane extracts (100 units cPLA2/mg protein ± 31 compared to 6 units/mg ± 1, n = 12, P < 0.01). There were no significant differences in the amount of total cPLA2 protein in synaptosomes isolated from vehicle treated cortical neurones and those treated for 1 hour with 200 nM PrP82-146, 200 nM PrP82-146scrambled, 1 μM PLAP, 100 nM Aβ1-42 or 100 nM Aβ42-1 (Table 1). Measurements were made after 1 hour, before any synapse degeneration was observed. Next specific antibodies (to cPLA2 phosphorylated at serine 505) were used to determine the amount of activated cPLA2 within synaptosomes. The amount of activated cPLA2 within synaptosomes was significantly increased following the addition of 200 nM PrP82-146, 1 μM PLAP or 100 nM Aβ1-42 but not after the addition of PrP82-146scrambled or Aβ42-1 (Table 1). Moreover, there was a significant inverse correlation between the amount of activated cPLA2in synaptosomes after 1 hour and the amount of synaptophysin in neurones after 24 hours following the addition of different amounts of PrP82-146 (range 1.25 to .005 μM), Pearson's coefficient = -0.76, P < 0.01 (Figure 7).
Table 1

PrP82-146 and Aβ1-42activated cPLA2within synapses.

Treatment

Total cPLA2 protein

(units/mg protein)

Activated cPLA2

(units/mg protein)

None (units)

100 ± 31

100 ± 19

200 nM PrP82-146

106 ± 18

773 ± 51 *

200 nM PrP82-146scrambled

95 ± 22

111 ± 34

1 μM PLAP

119 ± 30

928 ± 84 *

100 nM Aβ 1-42

109 ± 21

655 ± 62 *

100 nM Aβ 42-1

92 ± 27

121 ± 34

Primary cortical neurones were incubated with PrP, Aβ or PLAP peptides as shown for 1 hour. Synaptosomes were subsequently isolated from treated neurones and the amount of cPLA2 protein, and the amount of activated cPLA2 (phosphorylated at serine 505) were measured by ELISA. Values shown are the mean average amount of cPLA2 protein or activated cPLA2 (units/mg protein) ± SD, n = 12. * = amount of activated cPLA2 significantly greater than in control synaptosomes.

Figure 7

PrP82-146 increased activation of cPLA 2 in synapses. Correlation between the amounts of activated cPLA2 in synaptosomes isolated from primary cortical neurones 1 hour after the addition of varying concentrations of PrP82-146 and the amount of synaptophysin in cell extracts from primary cortical neurones incubated for 24 hours with the same concentrations of PrP82-146.

PAF antagonists protected against PrP82-146 induced synapse degeneration

The activation of PLA2 is the first step in the production of PAF [31] that has been shown to cause synapse degeneration in vitro [27]. The addition of PAF receptor antagonists (Hexa-PAF, CV6209 or ginkgolide B), in the range 0.1-10 μM, did not affect the amount of synaptophysin in cortical neurones. However, pre-treatment with 2 μM Hexa-PAF, 2 μM CV6209 or 1 μM ginkgolide B provided protection against PrP82-146 induced synapse degeneration (Figure 8). The EC50 of PrP82-146 in vehicle treated cortical neurones was 50 nM while the EC50 of PrP82-146 for neurones treated with 2 μM Hexa-PAF was 2 μM, for neurones treated with 2 μM CV6209 the EC50 was 5 μM and for neurones pre-treated with 1 μM ginkgolide B the EC50 was 20 μM. Pre-treatment with Hexa-PAF, ginkgolide or CV6209 also prevented the reduction in the synaptophysin content of cortical neurones incubated with 100 nM Aβ1-42 or 1 μM PLAP (Table 2). In a similar manner, the amount of synaptophysin in hippocampal neurones incubated with 50 nM PrP82-146 was significantly increased by pre-treatment with 1 μM ginkgolide B (97 units synaptophysin ± 9 compared to 18 ± 7, n = 6, P < 0.01), 2 μM Hexa-PAF (94 ± 11 compared to 18 ± 7, n = 6, P < 0.01) or 2 μM CV6209 (94 ± 11 compared to 18 ± 7, n = 6, P < 0.01).
Table 2

PAF receptor antagonists reduced synapse degeneration induced by Aβ1-42or PLAP.

 

Synaptophysin (units/106cells)

Treatment

Vehicle

Hexa-PAF

Ginkgolide B

CV6209

Vehicle

100 ± 6

98 ± 7

102 ± 5

96 ± 8

100 nM Aβ 1-42

32 ± 6

94 ± 6

98 ± 9

89 ± 8

1 μM PLAP

27 ± 7

95 ± 8

94 ± 8

82 ± 7

Primary cortical neurones were pre-treated with a vehicle control, or with PAF receptor antagonists (2 μM Hexa-PAF, 1 μM ginkgolide or 2 μM CV6209) for 1 hour prior to incubation with Aβ1-42 or PLAP as shown for 24 hours. Values shown are the mean average amount of synaptophysin (units/106 cells) ± SD, n = 12.

Figure 8

PAF receptor antagonists protected against PrP82-146 induced synapse degeneration. The synaptophysin content of cortical neurones pre-treated with a vehicle control (■), 1 μM ginkgolide B (), 2 μM Hexa-PAF () or 2 μM CV6209 (□) and subsequently incubated with varying concentrations of PrP82-146 for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 12.

Prostaglandin E2induced synapse degeneration

Prior studies showed that PAF facilitates the production of prostaglandins [32] suggesting that one or more of the prostaglandins produced in response to PrP82-146, Aβ1-42 or PLAP are responsible for synapse degeneration. This hypothesis was tested by treating cortical neurones with individual prostaglandins. We report that the addition of prostaglandin E2, but not other prostaglandins reduced the amount of synaptophysin in cortical neurones (Figure 9). Prostaglandin E2, acts via specific prostanoid E receptors [33] and pre-treatment with the prostanoid E receptor antagonist AH13205, but not the prostanoid D receptor antagonist BWA868C, prevented the loss of synaptophysin in cortical neurones incubated with PrP82-146, Aβ1-42, PLAP, PAF or prostaglandin E2 (Table 3). Taken together, these results show that the effects of PrP82-146 or Aβ1-42 on synapses were ultimately mediated through prostanoid E receptors.
Table 3

A prostanoid E receptor antagonist protected against synapse degeneration

 

Synaptophysin (units)

Treatment

Vehicle control

Prostanoid E receptor antagonist AH13205

Prostanoid D receptor antagonist BWA868C

Vehicle control

100 ± 6

99 ± 7

99 ± 3

200 nM PrP82-146

22 ± 5

87 ± 8

30 ± 7

100 nM Aβ 1-42

32 ± 6

93 ± 5

34 ± 6

1 μM PLAP

27 ± 7

91 ± 7

38 ± 6

10 nM PAF

31 ± 4

85 ± 9

32 ± 5

10 nM Prostaglandin E 2

30 ± 5

97 ± 3

33 ± 6

Primary cortical neurones were pre-treated with a vehicle control, a prostanoid E receptor antagonist (100 nM AH13205) or a prostanoid D receptor antagonist (100 nM BWA868C) for 1 hour prior to incubation with PrP82-146, Aβ1-42, PLAP, PAF or prostaglandin E2 as shown for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 9.

Figure 9

Prostaglandin E 2 caused synapse degeneration. The synaptophysin content of cortical neurones treated with varying concentrations of prostaglandins E2 () D2 (), F(□), I2 (■) or 15d-J2 (▲) for 24 hours. Values shown are the mean average amount of synaptophysin ± SD, n = 9.

Discussion

The addition of PrP82-146 reduced the synaptophysin content of cortical neurones indicative of a loss of synapses. This occurred at concentrations of peptide that did not affect neuronal survival [8], results consistent with in vivo observations that the loss of synapses in prion diseases occurs before any significant neuronal death is seen [1, 2]. PrP82-146 also damaged synapses in hippocampal neuronal cultures. The hippocampus is involved in memory formation and the loss of synapses in this area is consistent with the cognitive deficits that occur during the early stages of scrapie infections [3, 34].

A pharmacological approach was used to examine the molecular mechanisms involved in prion induced synapse degeneration. Critically, pre-treatment with selective PLA2 inhibitors reduced PrP82-146 induced synapse degeneration, whereas pre-treatment with inhibitors of some other common cell signalling pathways including phospholipase C had no affect. PrPSc is detected within synapses in CJD patients and experimental scrapie infections [2, 35, 36] and PrP82-146 was found within synaptosomes isolated from cultured neurones [8]. We found that pre-treatment with PLA2 inhibitors did not alter the amount of PrP82-146 found within synaptosomes, indicating the protective effect of these drugs was not due to the reduced binding of PrP82-146 to synaptic receptors, or a reduction in the trafficking of PrP82-146 to synapses.

Next, the possibility that PrP82-146 might activate cPLA2 resident within synapses was examined. Previous studies reported that PLA2 was found at synapse and regulated synaptic vesicle recycling [37, 38] and we observed that cPLA2 was highly enriched in synaptosomes. These observations imply that cPLA2 is part of the normal function of synapses and complete inhibition of cPLA2 may not be desirable as it may interfere with neurotransmission. However, the addition of PrP82-146 increased the amount of activated cPLA2 within synaptosomes nearly 8 fold suggesting that PrP82-146 induced activation of cPLA2 resident within synapses was responsible for synapse degeneration. This hypothesis was supported by our observations that there was a significant inverse correlation between the amount of activated cPLA2 and synaptic density and that synapse degeneration was also observed after the addition of PLAP. In addition, the effect of both PLAP and PrP82-146 on synapses was greatly reduced by pre-treatment with the cPLA2 inhibitors AACOCF3 and MAFP. Collectively, these results strongly suggesting that activation of an endogenous cPLA2 is a pivotal event in PrP82-146 mediated synapse degeneration.

The activation of PLA2 leads to the formation of a number of bioactive factors including prostaglandins, leucotrienes, docosanoids and PAF [31, 39]. PAF receptors are present at synaptic endings [40] and PAF facilitates neurotransmission [41]. However, higher concentrations of PAF are implicated in the neurotoxicity of glutamate, human immunodeficiency virus infection, prion diseases and AD [39, 42]. Reports that synaptic activity becomes excitotoxic in neurones exposed to elevated levels of PAF [43] may explain the role of PAF in these diseases. Here we showed that synapse degeneration induced by PrP82-146 was reduced by pre-treatment with PAF receptor antagonists, ginkgolide B, Hexa-PAF and CV6209. These PAF receptor antagonists also reduced synapse degeneration induced by PLAP suggesting that the effect of PrP82-146 and PLAP were a secondary effect mediated by activation of an endogenous cPLA2 and the production of PAF.

PAF affects the production of prostaglandin E2 [32] which is found in close association with PrPSc deposition and neuronal degeneration in scrapie [44]. In addition, the levels of prostaglandin E2are raised in the cerebrospinal fluid of patients with CJD [45]. While prostaglandin E2 may modify hippocampal synaptic transmission via a pre-synaptic prostanoid E receptors [46], higher concentrations cause synapse degeneration [27]. As shown in Figure 9 the addition of prostaglandin E2, but not other prostaglandins, caused synapse degeneration. The effects of prostaglandin E2 are mediated by specific membrane bound prostanoid E receptors [47] and synapse degeneration induced by PrP82-146 was reduced by pre-treatment with the prostanoid E receptor antagonist AH13205 suggesting that its effect was mediated through the prostanoid E receptor.

The results presented here may also be pertinent for other diseases in which synapse degeneration is common. For example, the neurotoxicity of Aβ1-42, widely believed to be the main toxin responsible for neurodegeneration in AD [23, 4850], was reduced following knockdown on cPLA2 [51, 52]. In this study we showed that Aβ1-42 strongly activated cPLA2 within synapses and that pre-treatment with PLA2 inhibitors protected against the synapse degeneration induced by Aβ1-42and naturally secreted Aβ oligomers (7PA2-CM). This observation is consistent with reports that inhibition of cPLA2 protected against cognitive impairment in a mouse model of AD [53]. A recent study indicated that PrPC acts as a receptor for Aβ1-42 oligomers [54]. PrPC also acts as a receptor for PrP peptides [55] suggesting that both PrP and Aβ1-42 activate PLA2 through their interaction with PrPC. We note that oligomers, rather than monomers, of PrP or Aβ1-42 are neurotoxic [5658]. Since oligomers of PrP and Aβ1-42, but not monomers, have the capacity to cross-link PrPC, our results support the hypothesis that it is the cross-linkage of PrPC by PrP or Aβ1-42 oligomers that activated cPLA2 leading to the production of PAF and prostaglandins. We propose that it is the persistent activation of cPLA2 by PrP82-146 or Aβ1-42 that results in high concentrations of PAF and prostaglandin E2 that cause synapse degeneration [27, 43].

Conclusion

Drugs that protect the synapse provide a rational strategy to treat many neurodegenerative diseases. In this study we showed that PLA2 inhibitors, PAF receptor antagonists and a prostanoid E receptor antagonist all protected against the synapse degeneration induced by PrP82-146 or Aβ1-42 in vitro. These peptides did not have a direct effect on synapses; rather synapse degeneration was caused after PrP82-146 or Aβ1-42 induced activation of an endogenous cPLA2 and the production of PAF and prostaglandin E2. Such results suggest that specific cPLA2 inhibitors or PAF receptor antagonists that are able to cross the blood-brain barrier should be considered for further testing in animal models of prion and Alzheimer's diseases.

Methods

Primary neuronal cultures

Primary cortical neurones were prepared from the brains of mouse embryos (day 15.5). Neuronal precursors were plated at 2 × 105 cells/well in 48 well plates in Ham's F12 containing 5% foetal calf serum (FCS) for 2 hours. Cultures were shaken (600 r.p.m for 5 minutes) and non-adherent cells removed by 3 washes in phosphate buffered saline (PBS). Neurones were grown in neurobasal medium (NBM) containing B27 components (PAA) for 7 days. Immunohistochemistry showed that the cells were greater than 97% neurofilament positive. Less than 3% stained for GFAP (astrocytes) or for F4/80 (microglial cells). Hippocampal neurones were prepared from the brains of adult mice as described [59]. Briefly, hippocampi were dissected and triturated in Ham's F12 containing 5% FCS, 0.35% glucose, 0.025% trypsin, and 0.1% type IV collagenase. After 30 minutes at 37°C, the cells were triturated again and the cell suspension was passed through a 100 μM cell strainer. Cells were collected by centrifugation, washed twice in Ham's F12 containing 5% FCS and plated at 2 × 105 cells/well in 48 well plates for 24 hours. Cultures were shaken (600 r.p.m for 5 minutes) to remove non-adherent cells, washed twice with PBS and neurones were cultured in NBM containing B27 components and 10 ng/ml glial-derived neurotrophic factor (Sigma) for 10 days. Neurones were incubated with test compounds for 3 hours before the addition of peptides and the amount of synaptophysin in treated neurones was measured 24 hours later. The survival of neurones was determined 5 days later using 25 μM thiazlyl blue tetrazolium for 3 hours; neuronal survival was reported as a percentage of controls (vehicle treated neurones).

Cell extracts

Neurones were homogenised in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate and mixed protease inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain, Pepstatin A and E-46 (Sigma)) and a phosphatase inhibitor cocktail including PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole (Sigma) at 106 cells/ml. Nuclei and cell debris was removed by low speed centrifugation (300 × g for 5 minutes). For immunoblots, cells were mixed 1:1 with Laemmli buffer containing β-mercaptoethanol, boiled for 5 minutes and run on a 12% polyacrylamide gel. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biotech) by semi-dry blotting. Membranes were blocked using 10% milk powder; synaptophysin was detected using a mouse monoclonal antibody (mAb) anti-synaptophysin SY38 (Abcam) and β-actin was detected by incubation with a mouse mAb (clone AC-74, Sigma). These were visualised using a combination of biotinylated rabbit anti-mouse IgG (Dako), extravidin-peroxidase and an enhanced chemiluminescence kit (Invitrogen).

Synaptophysin ELISA

Synaptophysin levels in cell extracts were measured by ELISA as described [9, 27]. A mouse monoclonal anti-synaptophysin MAB368 (Millipore) was used as a capture antibody and bound synaptophysin was detected using rabbit polyclonal anti-synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate (Sigma). Absorbance was measured on a microplate reader at 405 nm and synaptophysin content was calculated from a standard curve. Samples were expressed as "units synaptophysin" where 100 units was defined as the amount of synaptophysin in 106 vehicle treated neurones. A standard curve was generated from this sample using sequential log 2 dilutions (range 100 to 1.56 units).

Synaptosome preparations

Cortical neurones were pre-treated with drugs for 3 hours prior to the addition of 100 nM PrP82-146. After different time points (10, 30, 60 or 90 minutes) neurones were washed 3 times to remove unbound peptide and synaptosomes prepared on a discontinuous Percoll gradient as described [60]. Briefly, 106 cortical neurones were homogenized at 4°C in 1 ml of SED solution (0.32 M sucrose, 50 mM Tris-HCl, 1 mM EDTA, and 1 mM dithiothreitol, pH 7.4 and mixed protease/phosphates inhibitors (as above)). The preparation was centrifuged at 1000 × g for 10 minutes. The supernatant was transferred to a 4-step gradient of 3, 7, 15, and 23% Percoll in SED solution and centrifuged at 16,000 × g for 30 minutes at 4°C. The synaptosome fraction was collected from the interface of the 15% and 23% Percoll steps, washed twice (16,000 × g for 30 minutes at 4°C) and suspended in extraction buffer (150 mM NaCl, 10 mM Tris-HCl, 10 mM EDTA, 0.2% SDS and mixed protease/phosphatase inhibitors).

PrP82-146 ELISA

The amount of PrP82-146 in synaptosomes was determined by ELISA. Nunc Maxisorb Immunoplates were coated with 0.5 μg/ml of mouse mAb 3F4 (reactive with residues 109-112 of human PrP (Abcam)) this mAb does not bind to murine PrP [61]. Samples were applied and PrP82-146 was detected with 0.5 μg/ml biotinylated ICSM35 (D-gen, http://www.d-gen.co.uk), followed by streptavidin-alkaline phosphatase (Dako) and 1 mg/ml 4-nitrophenyl phosphate (Sigma). Absorbance was measured on a microplate reader at 405 nm and the amount of PrP82-146 in cell extracts was calculated by reference to a standard curve of PrP82-146.

cPLA2ELISA

The amount of cPLA2 in synaptosomes was measured by ELISA [62]. Nunc Maxisorb Immunoplates were coated with 0.5 μg/ml of mouse mAb anti-cPLA2, clone CH-7 (Upstate) and blocked with 10% FCS. Samples were incubated for 1 hour and the amount of cPLA2 was detected using a goat polyclonal anti-cPLA2 (Santa-Cruz Biotech). Bound antibodies were detected with biotinylated anti-goat IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured at 405 nm and the amount of cPLA2 was calculated from a standard curve using nonlinear regression. The amount of cPLA2 protein was expressed in units (100 units = amount of cPLA2 in synaptosomes isolated from 106 untreated primary cortical neurones). The activation of cPLA2 is accompanied by phosphorylation of the 505 serine residue which creates a unique epitope. To measure the amount of activated cPLA2, an ELISA using a mAb (anti-cPLA2, clone CH-7) combined with rabbit polyclonal anti-phospho-cPLA2 (Cell Signalling Technology) was used. Bound antibodies were detected with biotinylated anti-rabbit IgG (Dako), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Samples were expressed as "units activated cPLA2" where 100 units were defined as the amount of activated cPLA2 in synaptosomes derived from 106 untreated primary cortical neurones.

Drugs

U73122 and Ethyl-18-OCH3 were obtained from Biomol. Arachidonyl trifluoromethyl ketone (AACOCF3), aristolochic acids, ginkgolide B, 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine (Hexa-PAF), methyl arachidonyl fluorophosphonate (MAFP), prostaglandin G2, AH13205 and BWA868C were obtained from Sigma. Prostaglandins 15d-J2, E2, D2, F2α, H2 and I2 were obtained from Novabiochem. Stock solutions were dissolved in ethanol or di-methyl sulphoxide (DMSO) and diluted in medium to obtain final working concentrations. Vehicle controls consisted of equivalent dilutions of ethanol or DMSO in NBM.

Peptides

Peptides containing amino acids 82 to 146 of the human PrP protein (PrP82-146) corresponding to a PrP fragment found in certain prion-infected human brains [7], a control peptide (PrP82-146scrambled) were synthesised by solid-phase chemistry and purified by reverse-phase high performance liquid chromatography. A synthetic peptide containing the amino acid residues 1 to 42 of Aβ (Aβ1-42) of the Aβ protein and a control peptide consisting of the same amino acids in reverse order (Aβ42-1) were obtained from Bachem. Aβ peptides were first dissolved in hexafluoroisopropanol, lyophilised and subsequently solubilised and stored in DMSO. PLA2 Activating Peptide (PLAP) was purchased from Bachem. Stock solutions of peptides were thawed on the day of use and sonicated before dilution in culture medium and addition to cells.

CHO cells stably transfected with a cDNA encoding APP751 containing the Val717Phe familial AD mutation (referred to as 7PA2 cells) were cultured in DMEM with 10% FCS [28]. Conditioned medium (CM) from these cells contains stable Aβ oligomers (7PA2-CM). Conditioned medium from non-transfected CHO cells (CHO-CM) was used as controls.

Statistical Methods

Differences between treatment groups were assessed using two sample t tests or analysis of variance techniques. In all tests statistical significance was set at the 1% level.

List of abbreviations

(AD): 

Alzheimer's disease

(Aβ): 

amyloid-β

(AACOCF3): 

Arachidonyl trifluoromethyl ketone

(CHO): 

Chinese hamster ovary

(CM): 

conditioned medium

(CJD): 

Creutzfeldt-Jakob disease

(DMSO): 

di-methyl sulphoxide

(ELISA): 

Enzyme linked immunoassay

(Hexa-PAF): 

1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine

(MAFP): 

methyl arachidonyl fluorophosphonate

(NBM): 

neurobasal medium

(PBS): 

phosphate buffered saline

(PLA2): 

phospholipase A2

(cPLA2): 

cytoplasmic PLA2

(PLAP): 

PLA2 Activating Peptide

(PAF): 

platelet-activating factor

(PrP): 

prion protein.

Declarations

Acknowledgements

This work was supported by the European Commission FP6 "Neuroprion" Network of Excellence. We thank Professor Mario Salmona (Milan) for supplying PrP82-146 and PrP82-146scrambled peptides.

Authors’ Affiliations

(1)
Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane
(2)
Department of Veterinary Medicine, University of Cambridge

References

  1. Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP, Scott H, Rawlins JN, Perry VH: Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. EurJNeurosci. 2003, 17 (10): 2147-2155.Google Scholar
  2. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR: Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. NeuropathApplNeurobiol. 2000, 26 (1): 41-54.Google Scholar
  3. Johnston AR, Fraser JR, Jeffrey M, MacLeod N: Synaptic Plasticity in the CA1 Area of the Hippocampus of Scrapie-Infected Mice. Neurobiology of Disease. 1998, 5 (3): 188-195. 10.1006/nbdi.1998.0194.PubMedView ArticleGoogle Scholar
  4. Prusiner SB: Prions. ProcNatlAcadSciUSA. 1998, 95 (23): 13363-13383.View ArticleGoogle Scholar
  5. Siso S, Puig B, Varea R, Vidal E, Acin C, Prinz M, Montrasio F, Badiola J, Aguzzi A, Pumarola M, et al: Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathol. 2002, 103 (6): 615-626. 10.1007/s00401-001-0512-6.PubMedView ArticleGoogle Scholar
  6. Ferrer I, Puig B, Blanco R, Martí E: Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt-Jakob disease. Neuroscience. 2000, 97 (4): 715-726. 10.1016/S0306-4522(00)00045-2.PubMedView ArticleGoogle Scholar
  7. Salmona M, Morbin M, Massignan T, Colombo L, Mazzoleni G, Capobianco R, Diomede L, Thaler F, Mollica L, Musco G, et al: Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. JBiolChem. 2003, 278 (48): 48146-48153.Google Scholar
  8. Bate C, Tayebi M, Salmona M, Diomede L, Williams A: Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox Res. 2010, 17 (3): 203-214. 10.1007/s12640-009-9093-2.PubMedView ArticleGoogle Scholar
  9. Lipton AM, Cullum CM, Satumtira S, Sontag E, Hynan LS, White CL, Bigio EH: Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. Arch Neurol. 2001, 58 (8): 1233-1239. 10.1001/archneur.58.8.1233.PubMedView ArticleGoogle Scholar
  10. Elferink LA, Scheller RH: Synaptic vesicle proteins and regulated exocytosis. J Cell Sci. 1993, 17: 75-79.View ArticleGoogle Scholar
  11. Weimer RM, Jorgensen EM: Controversies in synaptic vesicle exocytosis. JCell Sci. 2003, 116 (18): 3661-3666. 10.1242/jcs.00687.View ArticleGoogle Scholar
  12. Wiedenmann B, Franke WW: Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. 1985, 41 (3): 1017-1028. 10.1016/S0092-8674(85)80082-9.PubMedView ArticleGoogle Scholar
  13. Daly C, Sugimori M, Moreira JE, Ziff EB, Llinas R: Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc Natl Acad Sci USA. 2000, 97 (11): 6120-6125. 10.1073/pnas.97.11.6120.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W, Kaye J, Manczak M: Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J AlzheimersDis. 2005, 7 (2): 103-117.Google Scholar
  15. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ: Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropath Exp Neurol. 2006, 65 (6): 592-601. 10.1097/00005072-200606000-00007.PubMedView ArticleGoogle Scholar
  16. Selkoe DJ: Alzheimer's Disease Is a Synaptic Failure. Science. 2002, 298 (5594): 789-791. 10.1126/science.1074069.PubMedView ArticleGoogle Scholar
  17. Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljarvi L, Koivisto E, Riekkinen : Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in alzheimer's disease. Neuroscience. 1995, 64 (2): 375-384. 10.1016/0306-4522(94)00422-2.PubMedView ArticleGoogle Scholar
  18. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991, 30 (4): 572-580. 10.1002/ana.410300410.PubMedView ArticleGoogle Scholar
  19. DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. AnnNeurol. 1990, 27 (5): 457-464.Google Scholar
  20. Hamos JE, DeGennaro LJ, Drachman DA: Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989, 39 (3): 355-361.PubMedView ArticleGoogle Scholar
  21. Vassar R, Citron M: Aβ-Generating Enzymes: Recent Advances in β and γ-Secretase Research. Neuron. 2000, 27 (3): 419-422. 10.1016/S0896-6273(00)00051-9.PubMedView ArticleGoogle Scholar
  22. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297 (5580): 353-356. 10.1126/science.1072994.PubMedView ArticleGoogle Scholar
  23. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. ProcNatlAcadSciUSA. 1998, 95 (11): 6448-6453.View ArticleGoogle Scholar
  24. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, et al: Self-assembly of Aβ1-42 into globular neurotoxins. Biochemistry. 2003, 42 (44): 12749-12760. 10.1021/bi030029q.PubMedView ArticleGoogle Scholar
  25. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK: Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain. J Neurosci. 2004, 24 (14): 3592-3599. 10.1523/JNEUROSCI.5167-03.2004.PubMedView ArticleGoogle Scholar
  26. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al: Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008, 14 (8): 837-842. 10.1038/nm1782.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Bate C, Tayebi M, Williams A: Ginkgolides protect against amyloid-β1-42-mediated synapse damage in vitro. Mol Neurodegen. 2008, 3 (1): 1-10.1186/1750-1326-3-1.View ArticleGoogle Scholar
  28. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ: Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. JBiolChem. 1995, 270 (16): 9564-9570.Google Scholar
  29. Pilane CM, LaBelle EF: cPLA2 activator peptide, PLAP, increases arachidonic acid release and apoptosis of vascular smooth muscle cells. J Cell Physiol. 2004, 198 (1): 48-52. 10.1002/jcp.10382.PubMedView ArticleGoogle Scholar
  30. Sattar AA, Haque R: Cytosolic PLA2 in zymogen granule fusion and amylase release: inhibition of GTP-induced fusion by arachidonyl trifluoromethyl ketone points to cPLA2 in G-protein-mediated secretory vesicle fusion. J Biochem. 2007, 141 (1): 77-84. 10.1093/jb/mvm007.PubMedView ArticleGoogle Scholar
  31. Francescangeli E, Domanska-Janik K, Goracci G: Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid MediatCell Signal. 1996, 14 (1-3): 89-98. 10.1016/0929-7855(96)01513-1.View ArticleGoogle Scholar
  32. Teixeira MM, al Rashed S, Rossi AG, Hellewell PG: Characterization of the prostanoid receptors mediating inhibition of PAF-induced aggregation of guinea-pig eosinophils. BrJ Pharmacol. 1997, 121 (1): 77-82. 10.1038/sj.bjp.0701107.View ArticleGoogle Scholar
  33. Sugimoto Y, Narumiya S: Prostaglandin E Receptors. J Biol Chem. 2007, 282 (16): 11613-11617. 10.1074/jbc.R600038200.PubMedView ArticleGoogle Scholar
  34. Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, Brandner S, Jefferys JG, Collinge J: Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007, 53 (3): 325-335. 10.1016/j.neuron.2007.01.005.PubMedView ArticleGoogle Scholar
  35. Kovacs GG, Preusser M, Strohschneider M, Budka H: Subcellular Localization of Disease-Associated Prion Protein in the Human Brain. Am J Pathol. 2005, 166 (1): 287-294.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Kitamoto T, Shin RW, Doh-Ura K, Tomokane N, Miyazono M, Muramoto T, Tateishi J: Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease.Google Scholar
  37. Moskowitz N, Schook W, Puszkin S: Regulation of endogenous calcium-dependent synaptic membrane phospholipase A2. Brain Res. 1984, 290 (2): 273-279. 10.1016/0006-8993(84)90944-2.PubMedView ArticleGoogle Scholar
  38. Moskowitz N, Schook W, Puszkin S: Interaction of brain synaptic vesicles induced by endogenous Ca2+-dependent phospholipase A2. Science. 1982, 216 (4543): 305-307. 10.1126/science.6278597.PubMedView ArticleGoogle Scholar
  39. Sun GY, Xu J, Jensen MD, Simonyi A: Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. 2004, 45 (2): 205-213. 10.1194/jlr.R300016-JLR200.PubMedView ArticleGoogle Scholar
  40. Marcheselli VL, Rossowska MJ, Domingo MT, Braquet P, Bazan NG: Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem. 1990, 265 (16): 9140-9145.PubMedGoogle Scholar
  41. Clark GD, Happel LT, Zorumski CF, Bazan NG: Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. Neuron. 1992, 9 (6): 1211-1216. 10.1016/0896-6273(92)90078-R.PubMedView ArticleGoogle Scholar
  42. Farooqui AA, Horrocks LA: Phospholipase A2-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly. The Neuroscientist. 2006, 12 (3): 245-260. 10.1177/1073858405285923.PubMedView ArticleGoogle Scholar
  43. Bellizzi MJ, Lu SM, Masliah E, Gelbard HA: Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest. 2005, 115 (11): 3185-3192. 10.1172/JCI25444.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Williams A, Van Dam AM, Ritchie D, Eikelenboom P, Fraser H: Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res. 1997, 754 (1-2): 171-180. 10.1016/S0006-8993(97)00067-X.PubMedView ArticleGoogle Scholar
  45. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJ, Knight R, Pocchiari M: Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology. 2002, 58 (1): 127-129.PubMedView ArticleGoogle Scholar
  46. Sang N, Zhang J, Marcheselli V, Bazan NG, Chen C: Postsynaptically Synthesized Prostaglandin E2 (PGE2) Modulates Hippocampal Synaptic Transmission via a Presynaptic PGE2 EP2 Receptor. JNeuroscience. 2005, 25 (43): 9858-9870. 10.1523/JNEUROSCI.2392-05.2005.View ArticleGoogle Scholar
  47. Wilson RJ, Rhodes SA, Wood RL, Shield VJ, Noel LS, Gray DW, Giles H: Functional pharmacology of human prostanoid EP2 and EP4 receptors. EurJPharmacol. 2004, 501 (1-3): 49-58.Google Scholar
  48. Lacor PN, Buniel MC, Furlow PW, Sanz Clemente A, Velasco PT, Wood M, Viola KL, Klein WL: Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease. JNeurosci. 2007, 27 (4): 796-807. 10.1523/JNEUROSCI.3501-06.2007.View ArticleGoogle Scholar
  49. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. J Neurosci. 2007, 27 (11): 2866-2875. 10.1523/JNEUROSCI.4970-06.2007.PubMedView ArticleGoogle Scholar
  50. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol. 2007, 8 (2): 101-112. 10.1038/nrm2101.PubMedView ArticleGoogle Scholar
  51. Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, et al: Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-β peptide. The FASEB Journal. 2004Google Scholar
  52. Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier J-L, Oster T, Pillot T: Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis. 2006, 23 (1): 178-189. 10.1016/j.nbd.2006.02.010.PubMedView ArticleGoogle Scholar
  53. Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, et al: Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008, 11 (11): 1311-1318. 10.1038/nn.2213.PubMedPubMed CentralView ArticleGoogle Scholar
  54. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature. 2009, 457 (7233): 1128-1132. 10.1038/nature07761.PubMedPubMed CentralView ArticleGoogle Scholar
  55. Lee KS, Linden R, Prado MAM, Brentani RR, Martins VR: Towards cellular receptors for prions. Reviews in Medical Virology. 2003, 13 (6): 399-408. 10.1002/rmv.408.PubMedView ArticleGoogle Scholar
  56. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ: Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability. J Biol Chem. 2002, 277 (35): 32046-32053. 10.1074/jbc.M201750200.PubMedView ArticleGoogle Scholar
  57. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, et al: In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 2007, 3 (8): e125-10.1371/journal.ppat.0030125.PubMedPubMed CentralView ArticleGoogle Scholar
  58. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416 (6880): 535-539. 10.1038/416535a.PubMedView ArticleGoogle Scholar
  59. Brewer GJ: Isolation and culture of adult rat hippocampal neurons. J Neurosci Meth. 1997, 71 (2): 143-155. 10.1016/S0165-0270(96)00136-7.View ArticleGoogle Scholar
  60. Thais ME, Carqueja CL, Santos TG, Silva RV, Stroeh E, Machado RS, Wahlheim DO, Bianchin MM, Sakamoto AC, Brentani RR, et al: Synaptosomal glutamate release and uptake in mice lacking the cellular prion protein. Brain Res. 2006, 1075 (1): 13-19. 10.1016/j.brainres.2005.12.045.PubMedView ArticleGoogle Scholar
  61. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, Wisniewski HM, Diringer H: Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987, 61 (12): 3688-3693.PubMedPubMed CentralGoogle Scholar
  62. Bate C, Tayebi M, Williams A: Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol. 2008, 6 (1): 8-10.1186/1741-7007-6-8.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© Bate et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.